Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term S-877489 (lisdexamfetamine mesilate) in pediatric ADHD
jRCT2080222719Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Safety outcomes. Started Jan 2015; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on jRCT2080222719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222719.